Key Highlights

  • CNSY most recently closed at $3.10, up about 2.65%.
  • Cerenome rebranded from Plus Therapeutics effective August 3, 2026, changing its ticker to CNSY from PSTV.
  • For 2025, Cerenome reported Revenue of about $5.21 million (down roughly 10%) and a net loss of about $22.4 million.
  • The company has secured multiple insurance-coverage agreements for its CNSide diagnostic, reported to expand access to more than 150 million covered lives.

Cerenome, Inc. (NASDAQ:CNSY) is a small clinical-stage company focused on cancers of the central nervous system, developing a radiotherapy candidate while commercializing a diagnostic test, and its stock gained ground even amid the challenges facing micro-cap biotechs. Recently rebranded from Plus Therapeutics, the company is pursuing treatments and diagnostics for difficult brain cancers, raising the question of whether it can build on the move.

Cerenome offers exposure to CNS oncology through both a therapeutic and a diagnostic, but its small size and financial position are central to the Investment case.

A rebrand, a therapy and a diagnostic

Cerenome rebranded from Plus Therapeutics to Cerenome, Inc. effective August 3, 2026, changing its ticker to CNSY from PSTV. The company develops REYOBIQ (rhenium obisbemeda), a radiotherapy candidate for recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancers, and it commercializes CNSide, a cerebrospinal-fluid assay used to detect and monitor cancer that has spread to the central nervous system.

Notably, the company has secured multiple insurance-coverage agreements for CNSide, reported to expand access to more than 150 million covered lives, which is important for adoption of a diagnostic. For 2025, Cerenome reported revenue of about $5.21 million (down roughly 10%) and a net loss of about $22.4 million, and its market Capitalization is small.

Business and financial position

Cerenome combines a clinical-stage therapeutic (REYOBIQ) targeting serious brain cancers with a commercialized diagnostic (CNSide) for detecting CNS metastases, addressing areas of significant unmet need. Its value rests on advancing REYOBIQ through clinical development toward potential approval and on growing CNSide adoption, aided by the insurance-coverage agreements.

As a micro-cap with modest revenue and ongoing losses, Cerenome depends on its cash and financing to fund development and commercialization, making the Balance Sheet and dilution central considerations.

Stock-market context

CNSY gained ground in recent trading, most recently closing at $3.10, up about 2.65%. Micro-cap biotech stocks are highly volatile, trading on clinical data, commercial progress, financing and sentiment, and can move sharply given their small size.

Cerenome's shares are likely to be sensitive to CNSide adoption and revenue, REYOBIQ clinical developments, cash runway and any capital raises. The bull case rests on the unmet need in CNS oncology and the dual therapeutic-diagnostic strategy, supported by CNSide's expanding coverage; the bear case focuses on the small revenue base, ongoing losses and funding needs.

What investors should watch

The key signals are CNSide revenue growth and adoption following the insurance-coverage agreements, clinical progress for REYOBIQ, cash runway, and any financing. Investors will be monitoring the pace of diagnostic adoption, regulatory and clinical developments for the therapy, competition, and dilution risk.

Whether Cerenome can build on the move depends on growing CNSide adoption, advancing REYOBIQ, and managing its cash, demonstrating that its combined approach to CNS oncology can build value despite the company's small scale. Micro-cap biotech names that emerge from corporate reinventions carry an unusually wide range of outcomes, because the value rests almost entirely on a small pipeline and on management's ability to fund it through long, capital-hungry development cycles. For the shares, the developments most likely to shift sentiment are concrete evidence of pipeline progress, clarity on the balance sheet and cash runway, and disciplined communication about milestones.